| 摘要 |
Disclosed are two novel crystalline forms δ and &egr; of perindopril erbumine, which are suitable as therapeutic substances in medicaments used for treating cardiovascular diseases, especially high blood pressure and cardiac insufficiency. Crystalline form &egr; is obtained by crystallizing perindopril erbumine from MTBE containing 1.5 to 2.5 % (v/v) of water at 30 to 45°C, preferably 34 to 45°C, crystallization expediently taking place by stirring. Crystalline form &egr; changes into crystalline form δ if the water is removed, practically by azeotropic distillation, preferably at 35 to 37°C, and stirring continues for at least 15 h at 30 to 45°C, preferably 35 to 37°C. Crystalline form δ can also be obtained by stirring crystalline form in tert-butyl methyl ether containing 0.9 to 1.4 % (v/v) of water at 33 to 38°C while inoculating the same with crystalline form δ. Crystalline form &egr; can further be obtained by stirring crystalline form α or &bgr; in tert-butyl methyl ether containing 0.9 to 1.4 % (v/v) of water at 28 to 35°C while inoculating the same with crystalline form &egr;, or by stirring crystalline form α or &bgr; in tert-butyl methyl ether containing 1.5 to 2.0 % (v/v) of water at 35 to 38°C. |
